source
- Ethyreal Bio raises $101M to develop antibody targeting Graves disease and thyroid eye diseaseEthyreal Bio, a Cambridge-based biotech that has just emerged from stealth mode, announced it has closed a $101 million financing round to advance its lead candidate. The company’s candidate, a mo…
- Sanofi halts rare disease trial as Parabilis launches record biotech IPO amid European pricing debateSanofi announced it is stopping a Phase 3 trial of its experimental drug riliprubart in a rare autoimmune disease after an interim analysis showed the treatment did not work. The pause adds to rec…